ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
Gynaecological cancers at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
200 organizations at ESMO 2026 present work in gynaecological cancers, led by cancer centres and hospitals. Between them they bring 1,520 presentations to the program. Most represented: Gustave Roussy, MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center. As of Nov 2, 2026.
Format
Top represented
Showing 1–1 of 200 organizations
| Organization | ESMO 2026 Attendance |
|---|---|
Gustave Roussy Villejuif, France | |
Comprehensive cancer centre in Villejuif, near Paris, France, affiliated with Paris-Saclay University. | Keynote Fri Oct 23 11:30–11:38 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Embedding co-creation to support immunotherapy de-escalation in the phase III OPT-PEMBRO trial in early triple-negative breast cancer Breast cancerNursing & supportive care Poster Fri Oct 23 13:00–15:00 Establishment and prospective evaluation of a national digital rare tumour advisory portal in Greece: A health services project in progress (TiP) Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 GIG-T (GETUG-T07): A phase 3 randomised study assessing thromboprophylaxis in good and intermediate prognosis advanced germ cell tumors Genitourinary cancersSarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 LEAH: A prospective multi-fluid cohort for cancer risk refinement and early detection Biomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Malnutrition, sarcopenia, hypermetabolism and micronutrient deficiencies at pancreatic cancer diagnosis: The NUTRIPAN cohort Gastrointestinal cancersNursing & supportive care Poster Fri Oct 23 13:00–15:00 Moving beyond PD-L1: Immune microenvironment biomarkers associated with durable benefit from immune checkpoint inhibitors in cervical cancer Gynaecological cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Neoadjuvant-based multimodality treatment in rare sinonasal tumors: A single-center cohort Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 Real-world data in adenoid cystic carcinoma: A retrospective single-center experience Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Chair Fri Oct 23 13:30–15:00 Abstract Fri Oct 23 14:00–14:10 Invited Discussant LBA23, LBA13 and LBA27 Breast cancer Talk Fri Oct 23 14:30–14:50 Therapeutic approaches in advanced/recurrent EC beyond CPIs and ADCs Gynaecological cancers Poster Fri Oct 23 15:15–16:00 A 25-gene T-cell exhaustion signature refines TLS-based prediction of immunotherapy benefit Lung & thoracic cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Characterization of the molecular and immune microenvironment landscape of synchronous vs metachronous renal cell carcinoma Genitourinary cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Genomic landscape and prognostic value of circulating tumor DNA (ctDNA) in pancreatic ductal adenocarcinoma (PDAC): A real-world cohort of 541 patients Gastrointestinal cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 In search for predictive biomarkers of redifferentiation treatment efficacy Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Prognostic value of the decipher prostate genomic classifier (GC) and neuroendocrine (NE) gene expression signatures in real-world de novo metastatic (M1) prostate cancer Genitourinary cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Talk Fri Oct 23 16:15–16:35 Novel AR targeted therapies Genitourinary cancers Abstract Fri Oct 23 16:25–16:37 Invited Discussant 1243RO and 1244RO Gynaecological cancers Talk Fri Oct 23 16:30–16:45 Basket trials: When is enough, enough? Biomarkers & precision oncology Talk Sat Oct 24 08:30–08:50 Talk Sat Oct 24 08:30–08:50 Presentation by Expert Genitourinary cancers Chair Sat Oct 24 08:30–10:00 Abstract Sat Oct 24 08:35–08:40 Talk Sat Oct 24 08:40–08:50 Welcome from ESMO Nursing & supportive care Talk Sat Oct 24 09:10–09:30 Systemic approach Sarcoma, CNS, head & neck and rare cancers Abstract Sat Oct 24 09:15–09:25 Abstract Sat Oct 24 09:45–09:55 Invited Discussant 1457O, 1458O and 1459O Haematological malignancies Abstract Sat Oct 24 10:15–10:20 Talk Sat Oct 24 11:30–11:37 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Communicating complexity in precision oncology: Qualitative insights to inform patient-facing digital twins Biomarkers & precision oncology Chair Sat Oct 24 12:00–12:50 ESMO-EACR: What oncologists should know about molecular oncology Biomarkers & precision oncology Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Genomic landscape of hormone receptor positive bone-only (BO) and visceral metastases (VM) metastatic breast cancer (HR+ BC) Breast cancerBiomarkers & precision oncology Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Photobiomodulation as a novel strategy for toxicity prevention in head and neck cancer Sarcoma, CNS, head & neck and rare cancersNursing & supportive care Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Socio-economic factors (SEF) and use of supportive care (SC) in highly symptomatic patients (pts) with breast cancer (BC) Breast cancerNursing & supportive care Chair Sat Oct 24 12:00–12:50 What oncologists should know about managing toxicities of novel therapies Nursing & supportive care Poster Sat Oct 24 12:00–12:45 ctDNA-detected PIK3CA mutations identify endocrine resistance to CDK4/6 inhibitors in hormone receptor-positive positive metastatic breast cancer (HR+ MBC) Breast cancerBiomarkers & precision oncology Talk Sat Oct 24 12:15–12:30 Bispecifics Nursing & supportive care Talk Sat Oct 24 12:15–12:30 DNA repair Biomarkers & precision oncology Satellite Sat Oct 24 14:05–14:17 Nuclear Medicine: partner for the Prostate Cancer journey Genitourinary cancers Chair Sat Oct 24 14:45–16:15 Emerging toxicities induced by antibody-drug conjugates Nursing & supportive care Talk Sat Oct 24 14:45–15:10 Pulmonary toxicities Nursing & supportive care Talk Sat Oct 24 15:00–15:15 Pheochromocytoma and paraganglioma Sarcoma, CNS, head & neck and rare cancers Talk Sat Oct 24 15:15–15:35 How will new technologies contribute to precision medicine? Biomarkers & precision oncology Talk Sat Oct 24 15:20–15:35 View of the interventional radiologist Gastrointestinal cancers Talk Sat Oct 24 15:45–16:05 NUT carcinomas, salivary gland cancers and pulmonary blastomas Lung & thoracic cancers Talk Sat Oct 24 15:45–16:05 What to do after optimal neoadjuvant therapy? Breast cancer Chair Sat Oct 24 16:30–18:15 Presidential Symposium I Lung & thoracic cancersMelanoma & skin cancersGenitourinary cancers Satellite Sat Oct 24 18:30–20:00 Ipsen - Treatment decisions that shape the journey in RCC and NETs Genitourinary cancersSarcoma, CNS, head & neck and rare cancers Satellite Sat Oct 24 18:30–18:33 Welcome Genitourinary cancersSarcoma, CNS, head & neck and rare cancers Satellite Sat Oct 24 18:33–18:43 Sequencing in an ever-changing landscape (RCC and NETs) Genitourinary cancersSarcoma, CNS, head & neck and rare cancers Satellite Sat Oct 24 18:43–19:23 Navigating the RCC treatment journey Genitourinary cancersSarcoma, CNS, head & neck and rare cancers Talk Sun Oct 25 08:30–08:35 Chair Sun Oct 25 08:30–10:00 Rapid oral 2: NSCLC, metastatic Lung & thoracic cancers Chair Sun Oct 25 08:30–10:00 Chair Sun Oct 25 08:30–09:45 Abstract Sun Oct 25 08:35–08:40 4245RO - Complementary roles of liquid biopsy and imaging in assessing tumor burden in metastatic cancer Biomarkers & precision oncology Abstract Sun Oct 25 08:45–08:57 Talk Sun Oct 25 08:55–09:15 Abstract Sun Oct 25 08:57–09:02 Abstract Sun Oct 25 09:29–09:44 Invited Discussant 2618RO, 2652RO and 2680RO Lung & thoracic cancers Chair Sun Oct 25 10:15–11:45 Chair Sun Oct 25 10:15–11:45 Chair Sun Oct 25 10:15–11:45 Emerging new systemic therapies for RCC Genitourinary cancers Talk Sun Oct 25 10:15–10:35 Novel HIF2a targeted agents and combination strategies Genitourinary cancers Talk Sun Oct 25 10:45–11:00 Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Satellite Sun Oct 25 13:05–13:15 Building Bridges in the Management of CSCC Melanoma & skin cancers Satellite Sun Oct 25 13:10–13:40 Satellite Sun Oct 25 13:15–13:35 Resectable or Not: Navigating the Gray Zones in Advanced CSCC Melanoma & skin cancers Satellite Sun Oct 25 13:35–13:50 Defining High-risk CSCC: Identifying Patients Who Need More Melanoma & skin cancers Satellite Sun Oct 25 13:40–13:45 Audience Q&A: Advanced prostate cancer Genitourinary cancers Talk Sun Oct 25 13:45–14:00 Satellite Sun Oct 25 13:50–14:20 Timing and Selection of Systemic Therapy in Resectable CSCC Melanoma & skin cancers Satellite Sun Oct 25 14:20–14:30 Audience Q&A Melanoma & skin cancers Chair Sun Oct 25 14:45–16:25 Talk Sun Oct 25 15:10–15:30 Neoadjuvant therapy: A global prescription for cure Melanoma & skin cancers Abstract Sun Oct 25 15:44–15:49 1538RO - First interim safety analysis of GORTEC 2024-03 IDEAL: Randomized phase II trial of induction treatment anti–PD-1 pucotenlimab (HX008) plus EGFR-ADC (becotatug vedotin (MRG003) versus EGFR-ADC alone followed by chemoradiotherapy in locally advanced head and neck squamous cell carcinoma Sarcoma, CNS, head & neck and rare cancers Abstract Sun Oct 25 15:44–15:49 Abstract Sun Oct 25 16:05–16:15 Talk Sun Oct 25 16:30–16:55 Abstract Sun Oct 25 16:42–16:54 Invited Discussant LBA5 Lung & thoracic cancersGastrointestinal cancers Talk Mon Oct 26 08:30–08:50 Chair Mon Oct 26 08:30–10:00 Chair Mon Oct 26 08:30–10:00 Navigating the wave of new therapies in gynaecologic cancers Gynaecological cancers Abstract Mon Oct 26 08:40–08:50 Talk Mon Oct 26 09:10–09:30 Abstract Mon Oct 26 09:38–09:50 Invited Discussant 3084O, 3893O and 3894O Nursing & supportive care Chair Mon Oct 26 10:15–11:45 Addressing the risk of second primary cancers Nursing & supportive care Chair Mon Oct 26 10:15–11:45 Talk Mon Oct 26 10:40–11:05 Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Liquid biopsy in fusion-driven NSCLC: Informative rates, resistance detection, and clinical impact Lung & thoracic cancersBiomarkers & precision oncology Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Systemic proteomics and muscle programs associated with cachexia in resectable head and neck cancer Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Poster Mon Oct 26 12:00–12:45 Talk Mon Oct 26 13:25–13:35 Talk Mon Oct 26 13:35–13:37 Abstract Mon Oct 26 14:45–14:50 Chair Mon Oct 26 14:45–15:45 Chair Mon Oct 26 14:45–16:15 Proffered paper: Non-metastatic NSCLC and other thoracic malignancies Lung & thoracic cancers Abstract Mon Oct 26 14:50–14:55 Abstract Mon Oct 26 15:07–15:12 Talk Mon Oct 26 15:10–15:25 How to simplify the algorithm of treatment of rare endocrine tumors Sarcoma, CNS, head & neck and rare cancers Abstract Mon Oct 26 15:53–16:05 Invited Discussant LBA64, 2519O and 2511O Lung & thoracic cancers Chair Mon Oct 26 16:30–17:45 Chair Mon Oct 26 16:30–18:00 IO-based systemic therapy in head and neck cancers Sarcoma, CNS, head & neck and rare cancers Talk Mon Oct 26 16:30–16:35 Presentation of case/condition Nursing & supportive care Abstract Mon Oct 26 16:42–16:54 Invited Discussant LBA9 Gynaecological cancersSarcoma, CNS, head & neck and rare cancers Chair Tue Oct 27 09:00–13:00 Talk Tue Oct 27 12:40–13:00 |
Find buyers in gynaecological cancers
Tell us what you sell and we’ll find the people at organizations working on gynaecological cancers most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse ESMO 2026 by
Organization type
Tumour type
Exhibit hall
Everyone
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction